It was previously noted that tigecycline usage might result in coagulopathy, which is typically characterized by a dose-dependent decrease in fibrinogen levels and a prolongation of prothrombin time and activated partial thromboplastin time [44]. The gene discussed is F2; the disease is blood coagulation disease.